Latest Period
Q1 2026
Security Snapshot
MapLight Therapeutics, Inc. - COMMON STOCK (MPLT) Institutional Ownership
CUSIP: 56565P103
13F Institutional Holders and Ownership History from Q4 2025 to Q1 2026
Institutions Reporting
80
Shares (Excl. Options)
24,700,477
Price
$20.33
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- MPLT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 24,700,477
- Total 13F value
- $502,152,842
- Portfolio coverage rank
- 0%
- Share change
- +1,498,505
- Value change
- +$34,264,805
- Number of holders
- 80
- Shares outstanding
- 42,399,432
- SEC-reported price per share
- $29.78
- Insider filing price
- $29.78
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MPLT - MapLight Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 56565P103.
- 80 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 74 to 80 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $405,121,994 to $502,152,842.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 80 institutions filings for Q1 2026.
Security key
56565P103
Latest holder period
Q1 2026
13F holders
80
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
MPLT full holder history
MapLight Therapeutics, Inc. SEC filings
MapLight Therapeutics, Inc. company facts
MapLight Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 56565P103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
MPLT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Catalyst4, Inc. | 45% | $361,842,414 | 19,697,464 | Catalyst4, Inc. | 28 Oct 2025 | |||
| Novo Holdings A/S | 8.4% | 3,686,622 | Novo Holdings A/S | 28 Oct 2025 | ||||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | $61,527,448 | 3,226,400 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 31 Dec 2025 | |||
| T. Rowe Price Investment Management, Inc. | 7.4% | +20% | $83,866,925 | +$9,044,844 | 3,137,558 | +12% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
As of 31 Mar 2026, 80 institutional investors reported holding 24,700,477 shares of MapLight Therapeutics, Inc. - COMMON STOCK (MPLT). This represents 58% of the company’s total 42,399,432 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NOVO HOLDINGS A/S | 8.7% | 3,686,622 | 0% | 6.1% | $74,949,025 |
| FCPM III SERVICES B.V. | 7.6% | 3,226,400 | 0% | 9.1% | $65,592,712 |
| T. Rowe Price Investment Management, Inc. | 6.6% | 2,801,937 | +0.1% | 0.04% | $56,964,000 |
| GOLDMAN SACHS GROUP INC | 4.7% | 1,994,873 | +3% | 0.01% | $40,555,768 |
| BlackRock, Inc. | 3.2% | 1,339,731 | +22% | 0% | $27,236,732 |
| Blue Owl Capital Holdings LP | 2.4% | 1,005,929 | +208% | 5.5% | $20,450,537 |
| Nan Fung Group Holdings Ltd | 2.3% | 971,253 | 0% | 16% | $19,745,573 |
| 5AM Venture Management, LLC | 2.2% | 950,011 | 0% | 5.4% | $19,313,724 |
| Sanofi | 2.2% | 912,041 | 0% | 5.5% | $18,541,794 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 719,820 | 0% | 0% | $14,633,941 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.4% | 611,447 | 0% | 4.4% | $12,430,718 |
| Velan Capital Investment Management LP | 1.2% | 492,893 | -5.6% | 6.3% | $10,020,515 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 481,201 | +24% | 0% | $9,785,392 |
| Siren, L.L.C. | 1.1% | 450,000 | 0% | 0.25% | $9,148,500 |
| Vestal Point Capital, LP | 0.99% | 420,000 | +9.1% | 0.24% | $8,538,600 |
| ADAR1 Capital Management, LLC | 0.88% | 374,909 | 0.46% | $7,621,900 | |
| BAKER BROS. ADVISORS LP | 0.86% | 364,705 | 0% | 0.04% | $7,414,453 |
| STATE STREET CORP | 0.8% | 339,116 | +48% | 0% | $6,894,228 |
| Freestone Grove Partners LP | 0.74% | 313,957 | +71% | 0.05% | $6,382,746 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.63% | 267,746 | +81% | 0.01% | $5,443,276 |
| RA CAPITAL MANAGEMENT, L.P. | 0.59% | 248,294 | 0.05% | $5,047,817 | |
| UBS Group AG | 0.56% | 236,512 | +1193% | 0% | $4,808,289 |
| FMR LLC | 0.48% | 204,501 | +22522% | 0% | $4,157,505 |
| Board of Trustees of The Leland Stanford Junior University | 0.47% | 199,231 | -0% | 0.48% | $4,050,366 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.45% | 192,139 | 2.8% | $3,906,186 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Latest
Q1 2026
Rows shown
1-2 of 2